LLY Looks 26.0% Undervalued on GF Value™

gurufocus.com · 2026-09-14

On September 14, 2026, Eli Lilly and Co (NYSE: LLY) announced significant traction in the U.S. market for its oral and injectable weight-loss medications, highl

TickrTrends take: Eli Lilly's current TickrTrends valuation verdict of Undervalued aligns with independent analysis suggesting the stock trades at a meaningful discount to intrinsic value. For investors monitoring valuation metrics, the gap between current price and estimated fair value represents the type of discrepancy that typically warrants attention in Healthcare sector analysis. The extent of this valuation gap may influence how valuation-focused investors prioritize LLY relative to other holdings or opportunities in their research process.

Read the full story at gurufocus.com →